InnoPharmax Inc.

Kaohsiung City

OncologyCAR-TPhase III

What changed

NIH R21 · $0.5M · Innovative Antibiotic Combinations for Hypervirulent Klebsiella pneumoniae

Jun 2025New grantJun 26, 2025Source filing (opens the source filing in a new tab)

Momentum

68no change

Some recent activity, at a steady rate.

Runway (estimate)

—unknown

No disclosed raise on file, so there is nothing to model from.

Stage

Phase III

The furthest-along thing in the public record. Not a projection.

Runway is an estimate: the last disclosed raise (SEC Form D) minus a modeled burn rate for the company’s stage and therapeutic area. It is not a disclosure, and companies routinely raise non-dilutive money we can’t see. How this is calculated.

Grant to raise

Every record Biodatica has resolved onto this company, newest first, each linked to the filing it came from. Where a source publishes no stable deep link for a record, the identifier is shown so you can look it up yourself.

Grant
R21 · $457k · non-dilutive
Jul 1, 2025
UNIVERSITY OF ILLINOIS AT CHICAGO · PI BULMAN, ZACKERY P. · NIAID · award ends Jun 30, 2027 · Innovative Antibiotic Combinations for Hypervirulent Klebsiella pneumoniae
NIH RePORTER · NIH RePORTER 11117874 (opens the source filing in a new tab)
Grant
R01 · $658k · non-dilutive
Jun 1, 2025
BOSTON UNIVERSITY (CHARLES RIVER CAMPUS) · PI HAN, XUE · NINDS · award ends May 31, 2030 · Cellular and network mechanisms of epilepsy and neuromodulation
NIH RePORTER · NIH RePORTER 11129235 (opens the source filing in a new tab)
Grant
S10 · $1.9M · non-dilutive
May 15, 2025
VANDERBILT UNIVERSITY MEDICAL CENTER · PI GORE, JOHN C · OD · award ends May 14, 2027 · Replacement of PET and MRI Scanners for Small Animal Imaging
NIH RePORTER · NIH RePORTER 11102860 (opens the source filing in a new tab)
Grant
R01 · $489k · non-dilutive
May 1, 2025
UNIVERSITY OF CALIFORNIA-IRVINE · PI HUNT, ROBERT F · NINDS · award ends Apr 30, 2030 · Targeting synaptic dysfunction in lissencephaly
NIH RePORTER · NIH RePORTER 11073528 (opens the source filing in a new tab)
Grant
R21 · $238k · non-dilutive
Apr 11, 2025
UNIVERSITY OF ILLINOIS AT CHICAGO · PI BULMAN, ZACKERY P. · NIAID · award ends Mar 31, 2027 · Structural, functional, and microbiological exploration toward synergistic dual aminoglycoside combinations
NIH RePORTER · NIH RePORTER 11057157 (opens the source filing in a new tab)
Grant
R01 · $706k · non-dilutive
Mar 1, 2025
UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHEN, LUJIA · NHGRI · award ends Feb 28, 2030 · Developing a Novel Causal Discovery Framework to Unveil Individualized Cell-Cell Communication Networks
NIH RePORTER · NIH RePORTER 11043882 (opens the source filing in a new tab)
Grant
R01 · $602k · non-dilutive
Sep 30, 2024
UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HAN, XIANLIN · NIA · award ends May 31, 2029 · The role of sulfatide in the development of tauopathy in the context of ADRD
NIH RePORTER · NIH RePORTER 11193445 (opens the source filing in a new tab)
Grant
R01 · $693k · non-dilutive
Sep 21, 2024
UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DUPREE, JAMES M · NICHD · award ends May 31, 2029 · How Health Insurance Benefit Design Affects Infertility Treatment and Birth Outcomes
NIH RePORTER · NIH RePORTER 11196071 (opens the source filing in a new tab)
Grant
R35 · $470k · non-dilutive
Jul 1, 2023
RESEARCH INST OF FOX CHASE CAN CTR · PI CHEN, LU · NIGMS · award ends May 31, 2028 · Telomerase RNP Prisonbreaks from Phase-Separated Nuclear Body
NIH RePORTER · NIH RePORTER 11089589 (opens the source filing in a new tab)
Grant
R01 · $753k · non-dilutive
Sep 30, 2022
JOHNS HOPKINS UNIVERSITY · PI SCHRACK, JENNIFER ANN · NIA · award ends Jun 30, 2027 · Novel application of Digital signals of movement, sleep and heart rhythms for detection of Alzheimer's Disease and Related Dementias
NIH RePORTER · NIH RePORTER 11132722 (opens the source filing in a new tab)
Trial
PHASE2/PHASE3 registered
Mar 29, 2022
Biliary Tract Cancer · RECRUITING · sponsor: InnoPharmax Inc. · Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
ClinicalTrials.gov · NCT05065957 (opens the source filing in a new tab)
Grant
R35 · $355k · non-dilutive
Aug 1, 2021
UNIVERSITY OF FLORIDA · PI CHEN, LI · NIGMS · award ends May 31, 2027 · Computational modeling of genetic variations by multi-omics integration todecipher personal genome
NIH RePORTER · NIH RePORTER 11088742 (opens the source filing in a new tab)
Grant
R01 · $671k · non-dilutive
Sep 28, 2012
VANDERBILT UNIVERSITY MEDICAL CENTER · PI GORE, JOHN C · NINDS · award ends May 31, 2028 · Biophysical Basis of Functional Connectivity by MRI
NIH RePORTER · NIH RePORTER 11114071 (opens the source filing in a new tab)

How this crosswalk was built

Confidence 100%Edges merged automatically, not yet reviewed by a human

Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator CHEN, LUJIA is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator HAN, XUE is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator BULMAN, ZACKERY P. is named on this company's filings"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["grant to an academic institution linked by a shared principal investigator"]}
Shared principal investigator or founder links the grant record at 0.75{"reasons":["principal investigator GORE, JOHN C is named on this company's filings"]}
new_entity links the trial record at 0.30{"reasons":["same therapeutic area"]}

Links score at or above 0.86 to merge automatically. Anything below that and above the review line goes to a human queue. Resolution is a judgment, and it can be wrong. How resolution works.

Event stream

Every scored event, newest first. This is what momentum is computed from.

NIH R21 · $0.5M · Innovative Antibiotic Combinations for Hypervirulent Klebsiella pneumoniae
Jun 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Biophysical Basis of Functional Connectivity by MRI
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.8M · Novel application of Digital signals of movement, sleep and heart rhythms for detection of Alzheimer's Disease and Related Dementias
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · How Health Insurance Benefit Design Affects Infertility Treatment and Birth Outcomes
Jun 2025Grant renewalSource (opens the source filing in a new tab)
NIH R35 · $0.4M · Computational modeling of genetic variations by multi-omics integration todecipher personal genome
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.6M · The role of sulfatide in the development of tauopathy in the context of ADRD
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Cellular and network mechanisms of epilepsy and neuromodulation
May 2025New grantSource (opens the source filing in a new tab)
NIH S10 · $1.9M · Replacement of PET and MRI Scanners for Small Animal Imaging
May 2025New grantSource (opens the source filing in a new tab)
NIH R35 · $0.5M · Telomerase RNP Prisonbreaks from Phase-Separated Nuclear Body
May 2025Grant renewalSource (opens the source filing in a new tab)
NIH R01 · $0.5M · Targeting synaptic dysfunction in lissencephaly
May 2025New grantSource (opens the source filing in a new tab)
Phase III trial registered: Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
Apr 2025Trial registeredSource (opens the source filing in a new tab)
Trial now recruiting: Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer
Apr 2025Trial recruitingSource (opens the source filing in a new tab)
NIH R21 · $0.2M · Structural, functional, and microbiological exploration toward synergistic dual aminoglycoside combinations
Apr 2025New grantSource (opens the source filing in a new tab)
NIH R01 · $0.7M · Developing a Novel Causal Discovery Framework to Unveil Individualized Cell-Cell Communication Networks
Feb 2025New grantSource (opens the source filing in a new tab)

Last disclosed raise

No Form D is on file, so there is no raise to model a runway from. That is why the runway reads “—” rather than a number. It does not mean the company has no money: grants, revenue and notes below the Form D threshold are all invisible here.

Something wrong on this page? The crosswalk is a judgment and we would rather hear it. Report a bad link.

Biodatica publishes impersonal research shown identically to every subscriber. This dossier is informational only, it is not investment advice, and the momentum and runway figures are estimates derived from public filings. The underlying records are U.S. government works. Disclosures · Data sources

Grant to raise

R21 · $457k · non-dilutive

R01 · $658k · non-dilutive

S10 · $1.9M · non-dilutive

R01 · $489k · non-dilutive

R21 · $238k · non-dilutive

R01 · $706k · non-dilutive

R01 · $602k · non-dilutive

R01 · $693k · non-dilutive

R35 · $470k · non-dilutive

R01 · $753k · non-dilutive

PHASE2/PHASE3 registered

R35 · $355k · non-dilutive

R01 · $671k · non-dilutive